"Not So Different" Episode 9: Biosimilars and Expanded Access to Cancer Treatment
This week on “Not So Different,” our guest is Ali McBride, PharmD, MS, BCPS. McBride is pharmacist who serves as the Clinical Coordinator for Hematology and Oncology at The University of Arizona Cancer Center. He’s also the lead author of a recent study that showed that using biosimilar filgrastim can expand patients’ access to treatment with obinutuzumab.
Among the great promises of biosimilar therapies is their ability to not only reduce costs for patients and healthcare systems, but also to make room in budgets for spending on other high-cost drugs, especially in treating cancer.
This week on “Not So Different,” our guest is Ali McBride, PharmD, MS, BCPS. McBride is pharmacist who serves as the Clinical Coordinator for Hematology and Oncology at The University of Arizona Cancer Center. He’s also the lead author of a recent study that showed that using biosimilar filgrastim can expand patients’ access to treatment with obinutuzumab.
McBride joined us from by phone from Arizona to discuss this study and more.
Subscribe to "Not So Different" on iTunes.
